<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073929</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT nr 2013-003862-15</org_study_id>
    <nct_id>NCT02073929</nct_id>
  </id_info>
  <brief_title>LIPT - Liraglutide in Polycystic Ovary Syndrome</brief_title>
  <acronym>LIPT</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens Faber</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated
      with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.

      The study investigates the effect af intervention with GLP-1-analog on risk markers of
      cardiovascular disease in women with PCOS.

      70 women will be included in af RCT.

      Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a
      beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Endogenous thrombin potential (ETP)</measure>
    <time_frame>At baseline and 26 weeks</time_frame>
    <description>Area under curve in a Thrombin Generation Test (TGT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma level of Plasminogen activator inhibitor -1 PAI-1</measure>
    <time_frame>At baseline and 26 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in plasma level of Brain Natriuretic Peptide (BNP)</measure>
    <time_frame>At baseline and 26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Comparsion of 2D and 3D ultrasound measurements of ovarian volume</measure>
    <time_frame>Base-line data</time_frame>
    <description>Comparsion of 2D and 3D ultrasound measurements of ovarian volume and antral follicle count, with MRI as gold standard.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide s.c. 1,8mg daily for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo s.c. 1,8mg daily for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>GLP-1-analogue Liraglutide</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS

          -  &gt;18 years

          -  premenopausal

          -  BMI &gt;25 og 25 and thereunder + insulin resistent

        Exclusion Criteria (including):

          -  actualt or intended pregnancy

          -  inadeqvat contraception

          -  hormonal contraception within 6 weeks

          -  metfoomin, GLP-1-analog or DPP IV inhibitor within 3 months

          -  medications affectiv hemostatic mechanisme

          -  diabetes or other severe comorbidity

          -  familar MEN
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Faber, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Medicine, Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Medicine and Dept. of Gyn-Obs, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital, Dept of Gynecology</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Medicine and Dept. of Obstetrics and Gynaecology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2014</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Jens Faber</investigator_full_name>
    <investigator_title>Professor, DSc, Senior Hospital Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 20, 2017</submitted>
    <returned>November 6, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

